Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | CCNC | P24863 | 12/20 | 0.47 |
| ▸ | CDK8 | P49336 | 12/20 | 0.47 |
| ▸ | CDK19 | Q9BWU1 | 12/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CDK9 | P50750 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7250825 | 1.00 | KDM4E (0.54) | KDM4EALDH1A1POLBRXFP1CCNC | |
| SCHEMBL7243279 | 0.83 | NPSR1 (0.60) | KDM4EALDH1A1POLBRXFP1CCNC | |
| SCHEMBL7243282 | 0.83 | NPSR1 (0.60) | KDM4EALDH1A1POLBRXFP1CCNC | |
| SCHEMBL1060812 | 0.71 | KDM4E (1.00) | KDM4EALDH1A1POLBRXFP1CCNC | |
| SCHEMBL7680675 | 0.68 | ALDH1A1 (0.53) | KDM4EALDH1A1POLBRXFP1CCNC | |
| SCHEMBL22803137 | 0.68 | DUSP10 (0.37) | KDM4EALDH1A1MEN1KMT2AGAA | |
| SCHEMBL6990680 | 0.66 | KDM4E (0.50) | KDM4EALDH1A1POLBRXFP1CCNC | |
| SCHEMBL6986479 | 0.65 | KDM4E (0.52) | KDM4EALDH1A1POLBRXFP1CCNC | |
| SCHEMBL18429106 | 0.65 | CCNC (0.79) | KDM4EALDH1A1POLBRXFP1CCNC | |
| SCHEMBL6990354 | 0.65 | CCNC (0.64) | KDM4EALDH1A1POLBRXFP1CCNC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030158245-A1 | Fused heterocyclic derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158245-A1 | Fused heterocyclic derivatives, their production and use | TST, STS, AHR | KDM4E 2331/4885ALDH1A1 327/4885POLB 4125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.